In this article, we will discuss 10 Best Long Term Healthcare Stocks to Buy.

Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies. As a non-cyclical sector, healthcare demand typically remains steady regardless of economic conditions, which can help provide portfolio balance during periods of market volatility. Long-term structural trends, including an aging global population and rising chronic disease prevalence, continue to support sustained demand for treatments, diagnostics, and healthcare services worldwide. At the same time, ongoing innovation across biotechnology, drug development, medical devices, and artificial intelligence applications is expanding treatment capabilities and improving research efficiency, creating new commercial opportunities across the sector.

Despite these favorable fundamentals, healthcare stocks have faced pressure from policy uncertainty, regulatory scrutiny, and shifting investor focus toward artificial intelligence and technology sectors. In the U.S., factors such as Medicare drug price negotiations under the Inflation Reduction Act, potential pharmaceutical tariffs, and proposed most-favored-nation drug pricing frameworks have weighed on sentiment. Additional concerns have included potential funding changes at regulatory and research agencies, evolving healthcare policy for insurance programs, and the ongoing patent cliff facing several large pharmaceutical products.

However, many of these risks appear increasingly reflected in valuations, with healthcare stocks trading near multi-decade lows relative to broader equity markets entering 2026. Meanwhile, regulatory systems remain functional, research funding outlooks appear more stable than previously feared, and innovation momentum continues across areas such as obesity, immunology, neurodegenerative disease, and AI-enabled drug discovery. Companies are also adapting through supply chain reshoring, direct-to-consumer distribution models, and strategic capital investment, positioning the sector for potential recovery as policy clarity improves.

With this context in mind, here is a list of the 10 best long term healthcare stocks to buy.

Our Methodology

For this article, we used an online stock screener to extract a list of healthcare stocks with over 75% revenue growth in the past five years. Next, we ranked those stocks in ascending order based on the number of hedge funds holding stakes in each stock as of Q3 2025. We assessed hedge fund ownership of each stock using Insider Monkey’s hedge fund database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

10 Best Long Term Healthcare Stocks to Buy

10. Ascentage Pharma Group International (NASDAQ:AAPG)

Number of Hedge Fund Holders: 2

5-year Revenue Growth: 130.37%

On January 14, Rodman & Renshaw initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $48 price target, citing the company’s differentiated hematology-focused pipeline and progress across multiple clinical-stage assets. The firm views Ascentage’s approach to addressing drug resistance in blood cancers as a key driver of upside as its next-generation programs advance toward clinical validation.

On February 5, 2026, Ascentage Pharma Group International (NASDAQ:AAPG) announced that its next-generation BTK-targeted protein degrader, APG-3288, received investigational new drug clearance from China’s Center for Drug Evaluation, shortly after securing a similar clearance from the U.S. FDA. The company plans to initiate a multicenter Phase I trial in patients with relapsed or refractory hematologic malignancies. Unlike traditional BTK inhibitors, APG-3288 uses PROTAC technology to degrade both wild-type and mutant BTK, potentially overcoming resistance seen with existing therapies. For investors, the dual IND clearances meaningfully de-risk the program and support faster global clinical development.

Ascentage Pharma Group International (NASDAQ:AAPG) is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers and age-related diseases. Founded in 2009, the company is headquartered in Suzhou, China. Ascentage Pharma is one of the 10 best long term healthcare stocks to buy.

9. Lipocine Inc. (NASDAQ:LPCN)

Number of Hedge Fund Holders: 2

5-year Revenue Growth: 132.45%

On January 21, H.C. Wainwright raised its price target on Lipocine Inc. (NASDAQ:LPCN) to $15 from $7 and maintained a Buy rating on the shares, citing the favorable safety profile observed for LPCN 1154. The firm sees the program as a potential value driver as it advances through late-stage development, particularly given the significant unmet need in postpartum depression and the potential for differentiation if safety and efficacy data remain strong.

On January 20, Lipocine Inc. (NASDAQ:LPCN) announced that enrollment and participant dosing have been completed in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The company expects to report topline safety and efficacy results early in the second quarter of 2026, according to CEO Mahesh Patel. Completion of enrollment marks an important milestone and reduces execution risk heading into a key clinical readout that could serve as a major catalyst for the stock if results are positive.

Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company focused on developing oral, lipid-based hormone therapies for men’s and women’s health. Founded in 1997 and headquartered in Salt Lake City, Utah, the company is advancing therapies targeting areas with meaningful unmet medical needs.

8. CorMedix Inc. (NASDAQ:CRMD)

Number of Hedge Fund Holders: 22

5-year Revenue Growth: 173.65%

CorMedix Inc. (NASDAQ:CRMD) announced that its board approved a share repurchase program authorizing up to $75 million in common stock buybacks, with the program set to remain in place through December 31, 2027. The company indicated the decision reflects confidence in its balance sheet strength, operating performance, and expected future cash flow generation, while maintaining flexibility to continue investing in internal growth initiatives and potential strategic opportunities. CorMedix expects share repurchases to begin as early as the first quarter of 2026. As of December 31, 2025, the company reported approximately $150 million in cash and cash equivalents and about 79.3 million shares outstanding, providing capacity to execute the program alongside ongoing business and clinical development priorities.

At the end of January, CorMedix Inc. (NASDAQ:CRMD) also saw insider activity, with Executive Vice President and General Manager of Healthcare Janet Dillione selling 10,000 shares for proceeds of $68,800. While modest in absolute dollar terms, the transaction represents a round-lot sale by a senior executive overseeing a core business segment. Such activity is often viewed as part of routine compensation management, though investors typically monitor insider transactions closely in smaller-cap biotech companies.

CorMedix Inc. (NASDAQ:CRMD) is a commercial-stage biopharmaceutical company founded on July 28, 2006, and headquartered in Berkeley Heights, New Jersey. The company focuses on developing and commercializing therapies to prevent and treat infections, with DefenCath targeted at patients undergoing hemodialysis.

7. Delcath Systems, Inc. (NASDAQ:DCTH)

Number of Hedge Fund Holders: 23

5-year Revenue Growth: 88.10%

On January 9, Clear Street raised its price target on Delcath Systems, Inc. (NASDAQ:DCTH) to $29 from $28 while maintaining a Buy rating following the release of preliminary fourth-quarter results. The firm noted that its product Hepzato has become a steadier revenue contributor, with improved predictability and sufficient cash generation to support expansion into additional indications.

On the same day, Delcath Systems, Inc. (NASDAQ:DCTH) reported preliminary, unaudited results showing expected fourth-quarter revenue of approximately $20.7 million and full-year 2025 revenue of $85.2 million. Performance was driven primarily by Hepzato sales, which totaled about $19.0 million for the quarter and $78.8 million for the year, with Chemosat contributing the remainder. The company reported strong operating cash flow and minimal leverage, supporting internal funding of clinical programs and a previously announced share repurchase plan.

Delcath Systems, Inc. (NASDAQ:DCTH) was founded on August 5, 1988, and is headquartered in Queensbury, New York. The company develops interventional oncology therapies for primary and metastatic liver cancers, including the Hepzato and Chemosat Hepatic Delivery System.

6. RxSight, Inc. (NASDAQ:RXST)

Number of Hedge Fund Holders: 25

5-year Revenue Growth: 128.61%

On January 30, William Blair initiated coverage of RxSight, Inc. (NASDAQ:RXST) with a Market Perform rating and no price target. The firm cited stalled sales growth in 2025 following strong adoption from early users between 2021 and 2024, noting that evidence of a sustained commercial reacceleration is needed despite the stock trading at a discount to peers.

During its third-quarter 2025 earnings call, RxSight, Inc. (NASDAQ:RXST) narrowed full-year revenue guidance to a range of $125 million to $130 million, compared with prior guidance of $120 million to $130 million. The company highlighted continued progress in its international rollout, particularly in Asia and Europe, supported by regulatory approvals and commercial infrastructure investments. Management indicated that these regions are expected to contribute incrementally to revenue over a multiyear period as adoption increases.

RxSight, Inc. (NASDAQ:RXST) was founded in 1997 and is based in Aliso Viejo, California. The company develops adjustable intraocular lenses used in cataract surgery, allowing post-operative vision correction.

5. Ardelyx, Inc. (NASDAQ:ARDX)

Number of Hedge Fund Holders: 30

5-year Revenue Growth: 129.14%

Ardelyx, Inc. (NASDAQ:ARDX) reported preliminary, unaudited product revenue results for the fourth quarter and full year 2025, along with expected product revenue for 2026 and an updated long-term outlook for Ibsrela. The company delivered strong commercial performance in 2025, with Ibsrela revenue increasing 73% year over year, while maintaining patient access to Xphozah. Ardelyx also advanced its development pipeline by initiating a Phase 3 program for Ibsrela in chronic idiopathic constipation and beginning work on a next-generation NHE3 inhibitor, RDX10531. Entering 2026, the company indicated it is positioned for continued growth, supported by expanding commercial opportunities, ongoing pipeline development, and a solid cash position. Ardelyx emphasized its focus on advancing first-in-class therapies addressing unmet medical needs while investing in commercialization and development efforts to support long-term value creation.

Recent developments include the initiation of a Phase 3 trial evaluating Ibsrela in chronic idiopathic constipation, a larger and underpenetrated indication that could expand the drug’s addressable market. Ardelyx, Inc. (NASDAQ:ARDX) continues to report strong year-over-year revenue growth for Ibsrela, alongside increasing Xphozah sales. Updated guidance reflects expectations for Ibsrela to exceed $1 billion in peak sales, supported by patent protection extending to 2041. Advancement of the next-generation NHE3 inhibitor RDX10531 adds an additional pipeline asset alongside ongoing commercialization efforts.

Ardelyx, Inc. (NASDAQ:ARDX) was founded in October 2007 and is headquartered in Waltham, Massachusetts. The company develops therapies targeting gastrointestinal, cardio-renal, and metabolic diseases.

4. TG Therapeutics, Inc. (NASDAQ:TGTX)

Number of Hedge Fund Holders: 37

5-year Revenue Growth: 364.59%

On January 15, Goldman Sachs raised its price target on TG Therapeutics, Inc. (NASDAQ:TGTX) to $39 from $37 while maintaining a Neutral rating. The firm expects the stock to trade higher following the company’s disclosure of 2026 revenue guidance of $875 million to $900 million and noted that Phase 3 enrollment for the subcutaneous formulation of BRIUMVI is progressing ahead of expectations.

During its Q3 2025 earnings call, TG Therapeutics, Inc. (NASDAQ:TGTX) reported total revenue of $161.7 million, representing a 93% increase year over year and a 15% increase sequentially. U.S. BRIUMVI net sales reached approximately $153 million for the quarter, exceeding both internal targets and Street expectations. Management emphasized continued financial discipline despite accelerating commercial momentum, with a focus on sustaining long-term growth while maintaining profitability. The company reported GAAP net income of $390.9 million for the quarter, reflecting strong operating leverage as BRIUMVI adoption expands.

TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company focused on developing therapies for autoimmune diseases, particularly multiple sclerosis. The company was founded in 1993 and is headquartered in Morrisville, North Carolina, and is among the 10 best long term healthcare stocks to buy.

3. Oscar Health, Inc. (NYSE:OSCR)

Number of Hedge Fund Holders: 40

5-year Revenue Growth: 79.82%

On January 9, UBS upgraded Oscar Health, Inc. (NYSE:OSCR) to Neutral from Sell and raised its price target to $17 from $12. The firm cited better-than-expected exchange enrollment trends despite the expiration of enhanced subsidies and noted that the shares appear fairly valued at current levels.

In the third quarter of 2025, Oscar Health, Inc. (NYSE:OSCR) reported a 23% year-over-year increase in total revenue to approximately $3.0 billion. Medical loss ratio increased by 380 basis points to 88.5%, reflecting cost pressures during the period. The company also outlined plans to expand into 20 states for 2026, including new entries into Alabama and Mississippi, while launching additional products such as HelloMeno. Management highlighted ongoing investments in technology, including the integration of AI tools through its Oswell platform, aimed at improving operational efficiency and member engagement.

Oscar Health, Inc. (NYSE:OSCR) was founded in 2012 as a technology-focused health insurance company. The company seeks to improve access and affordability through digital tools, virtual care, and data-driven plan design.

2. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 42

5-year Revenue Growth: 121.86%

On January 28, Barclays assumed coverage of Moderna, Inc. (NASDAQ:MRNA) with an Equal Weight rating and a $25 price target as part of a broader biotechnology coverage expansion. The firm expressed a constructive view on the sector heading into 2026, citing undervaluation, expected M&A activity, and improving industry fundamentals as supportive factors.

During Moderna’s third-quarter 2025 earnings call, the company reported revenue of approximately $1.0 billion, driven primarily by sales of its approved vaccines, including Spikevax, mNEXSPIKE, and mRESVIA. Moderna, Inc. (NASDAQ:MRNA) ended the quarter with $6.6 billion in cash and investments and guided to a year-end balance of $6.5 billion to $7.0 billion. The company emphasized disciplined capital management while continuing to fund pipeline development across multiple therapeutic areas.

Moderna, Inc. (NASDAQ:MRNA) was founded in September 2010 and is headquartered in Cambridge, Massachusetts. The company focuses on developing medicines using messenger RNA technology. Moderna is second on the list of 10 best long term healthcare stocks to buy.

1. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Number of Hedge Fund Holders: 43

5-year Revenue Growth: 351.71%

On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The firm cited the company’s track record in drug development and assigned probability-of-success assumptions across multiple programs, including PN-8047, its IL-4R antagonist, and obesity assets.

In early February, a company director sold 20,000 shares in a transaction valued at approximately $1.7 million, an event monitored by investors alongside ongoing pipeline developments. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) recently reported having two potential late-stage assets, Icotrokinra and Rusfertide, with NDAs submitted in 2025 for plaque psoriasis and polycythemia vera, respectively. The company also expects multiple Phase 2 and Phase 3 readouts across immunology, hematology, and obesity indications. Existing partnerships with Johnson & Johnson and Takeda include milestone and royalty structures that support non-dilutive funding.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was founded on August 22, 2006, and is headquartered in Newark, California. The company develops peptide-based therapies targeting rare diseases, hematology, and immunology.

While we acknowledge the potential of PTGX as a great healthcare stock to invest in the long term, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PTGX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.